Gilead Sciences Inc. (NASDAQ:GILD) recently announced that one of its experimental Hepatitis C (HCV) combination drugs has been successful against multiple virus strains in a large-scale clinical trial. The results will help further strengthen Gilead’s position as the market leader in the HCV space, giving it yet another advantage over rival AbbVie Inc. (NYSE:ABBV).
The late stage clinical trial enrolled 624 patients who were suffering from one or a combination of the six strains (genotypes) of HCV. The combination drug, velpatasvir and sofosbruvir, proved to be effective in clearing HCV by 99% when administered for the standard treatment duration of 12 weeks. According to Gilead’s statement released on Monday, three other linked clinical studies proved that the drug can successfully treat multiple strains.
Hey, check out all the research scientist jobs. Post your resume today!
